Stops or significantly reduces hair loss in as little as 4 to 6 weeks
EUCAPILŪ has been registered as a cosmetic product within the European Union and meets
all of the criteria laid out in the U.K. Dti Cosmetic (Safety) Regulations 2004 and the E.U.
Cosmetics Directive 76/786/EEC. It is currently available for sale as an OTC product in various
countries throughout the European Union and beyond.
EUCAPILŪ in more detail
The Androgenic Hormones (AH) can affect the hair only via the Androgenic Receptor (AR), a
cellular protein transcription factor which interacts with a specific region of DNA. Thus, both
testosterone and its more potent analog, 5-alpha-dihydrotestosterone (DHT), must bind to the
AR in the hair follicles in order to affect hair.
Antiandrogens (AA) are systemically administered drugs which block AH binding to the AR.
Originally developed for the treatment of prostate cancer, these compounds, since they block
AR systemically, have considerable side effects, including loss of libido and male sexual
functions. These drugs cannot be used in males for the treatment of AGA, not even
topically, since they are well resorbed trom the skin and are stable in vivo.
Topical steroidal AA such as cyproterone acetate, chlormadinone acetate and spironolactone were not successful, supposedly because of poor absorption into the skin; some also have a skin irritation potential.
Currently available for treatment of AE and AGA are the topical Minoxidil and its analogs, such
as Aminexil and finasteride. Minoxidil, an antihypertensive drug, incidentally prevents
hair loss, and to an extent, promotes regrowth, but only in the vertex scalp; the activity is
tentatively explained, among others, by activation of the prostaglandin endoperoxide synthase1,
increase of the local blood flow, suppression of bacterial infection and/or by a modification of
the AH metabolism in the dermal papilla.
Mechanism of Action of EUCAPILŪ (Fluridil) or 'How it actually works'
In an effort to develop a more powerful and safe inhibitor of the androgen receptor, the
laboratories at Biophysica Inc. in California in collaboration with the research laboratories of a
Czech biotech-pharma company, Interpharma Praha, developed a novel class of substances
which proved to render the androgen receptor inactive in a novel way.
EUCAPILŪ is a powerful and safe inhibitor of the androgen receptor. The basis of EUCAPILŪ
Hair Treatment is the patented active ingredient FluridilŪ which is an androgenic receptor
Suppressor.
There are several alopecias known, but the prevalent type, both in men and women, is
androgenic, i.e. caused by the androgenic hormones (AH) affecting the scalp hair follicles. AH
are important in the physiology of skin; they promote the growth of the beard and of the body
hair throughout life. The growth of the scalp hair also depends on AH, but only in early life. It is
not yet explained why AH, with increasing age, switch from promoting growth of the scalp hair
to its loss, inducing conditions known as an androgenic effluvium (AE) and alopecia (AGA).
Finasteride taken orally and daily suppresses conversion of testosterone into
dihydrotestosterone (DHT), thus lowering AH activity in the scalp. The studies indicate about
half of the men achieve slight to moderate improvement in the anterior mid scalp and in
approximately one-half, the effluvium is arrested. Side effects include decreased libido and
erectile function, which disappear after drug withdrawal. No studies are yet available to prove
whether such a long-term systemic manipulation of hormonal balance is harmless.
Clearly, a topically active antiandrogen suppressing rather than blocking the cutaneous AR,
while not irritating and not absorbable from skin into the body, would be useful in the therapy of
AH dependent cutaneous afflictions. Interpharma a.s in tandem with Biophysica Inc designed and synthesized a number of novel antiandrogens and found that some, rather than blocking, suppressed the AR in a concentration and time-dependent fashion. Some of these compounds showed extremely low
or no systemic bioavailability upon oral and/or topical application. The compound with the best
overall properties for topically active suppression of cutaneous androgen receptors proved to
be BP-766 (Fluridil), the active ingredient of EUCAPILŪ, since it is rapidly biodegradable into
two components of high systemic and local tolerance devoid of antiandrogenic activity. It
therefore offers a novel and sound concept in handling cosmetically, androgenic effluvium and
incipient alopecia.
Summary:
In EUCAPILŪ we have a safe, tried and tested, clinically proven, effective treatment for
hair loss associated with androgenetic alopecia.
